Medicure Inc V.MPH

Alternate Symbol(s): MCUJF

Healthcare Biotechnology

Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

TSXV:MPH - Post by User

Medicure Inc

Bullboard Posts

Comment by eSnowdenon Sep 12, 2014 3:10pm

187 Views

Post# 22931758

RE:to JCW and eSnowden re Apicore deal

Drug manufacturers collect manufacturing fees, pharma co's like Medicure collect sales revenue--manufacturing fees are a small fraction in comparison to pharma sales revenue. The only drug manufacturer I have seen do ok is US-based Xoma, who at one time, manufactured biologics for Genentech. They had a royalty agreement based on sales of the drugs they manufactured and since Genentech is known for producing blockbuster-type drugs--this can be advantageous. Under normal circumstances, contract drug manufacturers profit margins are minute in comparison to pharma co's. I would like to see how much profit Apicore made on the $10mm.

Again, Medicure should focus primarily on the transdermal formulation of Aggrastat to grow revenues.

Bullboard Posts

This AI stock is disrupting the event tickets monopoly